---
title: "HANSOH PHARMA's new drug HS-20197 approved for clinical trials in advanced solid tumors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299159008.md"
description: "According to a report from Economic Information Agency on the 16th, HANSOH PHARMA announced that its self-developed Class 1 new drug injectable HS-20197 has received the Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for \"advanced solid tumors.\" (hp)"
datetime: "2026-09-16T09:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299159008.md)
  - [en](https://longbridge.com/en/news/299159008.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299159008.md)
generator: "portal-rs"
---

# HANSOH PHARMA's new drug HS-20197 approved for clinical trials in advanced solid tumors

According to a report from Economic Information Agency on the 16th, HANSOH PHARMA (03692) announced that its self-developed Class 1 new drug injectable HS-20197 has received the clinical trial approval notice from the National Medical Products Administration (NMPA) of China, intended for conducting clinical trials for "advanced solid tumors." (hp)

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)

## Related News & Research

- [Hansoh Pharma’s TYK2 Psoriasis Drug Clears Key Phase III Trial Milestone](https://longbridge.com/en/news/299569130.md)
- [Hansoh’s Osteosarcoma Drug HS-20093 Wins NMPA Priority Review in China](https://longbridge.com/en/news/299744971.md)
- [Hansoh Pharma says Phase 3 HS-10374 psoriasis trial meets co-primary endpoints](https://longbridge.com/en/news/299571756.md)
- [G Sachs: HANSOH PHARMA  Ris-rez Phase III Study Strongly Validated, Safety and Earlier-line Expansion in Focus](https://longbridge.com/en/news/298992599.md)
- [JPM: HANSOH PHARMA  Targeting B7-H3 ADC Product Posts Positive Lung Cancer Treatment Data, Maintains Overweight Rating](https://longbridge.com/en/news/298863585.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**